|
 |
AntihemophilicThis page contains recent news articles, when available, and an overview of Antihemophilic but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Shipments of the Company’s current recombinant factor VIII product, ReFacto® Antihemophilic Factor (Recombinant) in the United States will be discontinuedPR-USA.net (press release), Wyeth Pharmaceuticals introduces new hemophilia drug Sep 9, 2008 Shipments of the company's current recombinant factor VIII product, ReFacto antihemophilic factor in the US will be discontinued as of May 31, 2009.Trading Markets (press release), CSL Behring initiates voluntary recall of human antihemophilic factor Aug 20, 2008 CSL Behring LLC has initiated a voluntary recall of four lots of its human antihemophilic factor product -- Monoclate-P -- because they do not meet theSmartBrief, CSL Behring's Innovative HeliTrax(SM) System Helps Physicians ... Aug 25, 2008 25 -- Hemophilia A patients who use Helixate(R) FS, Antihemophilic Factor (Recombinant), and their treatment providers are now tracking treatment progressEarthtimes (press release), CSL Behring Provides $1.2M Grant for World's First Study of ... Aug 18, 2008 Products include Humate P® Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized, for the treatment of von Willebrand Disease,PR Newswire (press release), Amgen and Wyeth Statement on the FDA Safety Announcement Regarding ... Sep 4, 2008 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA)StreetInsider.com (subscription), Bayer HealthCare and Maxygen Announce Hematology Agreement - Jul 1, 2008 About Kogenate® FS/KOGENATE® Bayer Kogenate® FS (Antihemophilic Factor [Recombinant]) / KOGENATE® Bayer (Recombinant Coagulation Factor VIII [octocog alfa]) WELT ONLINE, Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R ... - May 31, 2008 Kogenate(R) FS (Antihemophilic Factor [Recombinant]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently PR Newswire (press release), National Hemophilia Foundation Applauds First von Willebrand ... - May 6, 2008 Products include Humate-P(R) Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized, for the treatment of von Willebrand disease, PR Newswire (press release), Bayer HealthCare's New EZ-Log Web Client Provides Additional ... - 23 Apr 2008 Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently Medical News Today (press release), Bayer donates €250000 for patients with hemophilia and provides ... - Apr 17, 2008 Approximately 400000 people around the world have hemophilia A. Kogenate FS (Antihemophilic Factor [Recombinant]) / KOGENATE Bayer (Recombinant Coagulation PharmaLive.com (press release), CSL Behring Signs Agreements With Canadian Blood Services and Hema ... - Apr 3, 2008 Humate-P(R) is a stable, purified, sterile, lyophilized concentrate of Antihemophilic Factor (Human) and von Willebrand Factor (vWF) (Human) complex used FOXBusiness Wyeth Reports Earnings Results for the 2008 First Quarter - Apr 22, 2008 In February, the US Food and Drug Administration (FDA) approved XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor MSN Money Baxter Reports Solid First Quarter Financial Results and Raises ... - Apr 17, 2008 Driving this performance was robust growth from several products used for the treatment of hemophilia and immune disorders, including ADVATE [Antihemophilic Biloxi Sun Herald, Contracts Provide Canadians With Access And Choice To Critical ... - Apr 3, 2008 Under the new, multi-year agreements, Baxter will supply Canadian Blood Services and Héma-Québec with commercial products, including ADVATE® [Antihemophilic Medical News Today (press release), Recombinant Antihemophilic Factor, Xyntha™ Gets FDA Nod For ... - Feb 24, 2008 A recombinant antihemophilic factor (Xyntha™ | Wyeth), free from both albumin and plasma, has been approved by the FDA for the treatment of hemophilia A. Medi News Direct, Wyeth's XYNTHA Approved by FDA for Treatment of Hemophilia A - Feb 21, 2008 XYNTHA(TM) Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for the control and prevention of bleeding episodes in patients with FOXBusiness Wyeth's Xyntha gets FDA approval for treatment of hemophilia A - Feb 21, 2008 The US Food and Drug Administration Thursday licensed Wyeth (NYSE:WYE PR) (NYSE:WYE) Pharmaceuticals Inc.'s Xyntha Antihemophilic Factor Plasma, CNNMoney.com FDA approves Wyeth's Xyntha treatment for hemophilia A - Feb 21, 2008 ...in the US The treatment, called Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free, is a genetically-engineered version of factor VIII, MarketWatch Dyax Corp receives first market approval from Licensing and Funded ... - Feb 29, 2008 ...has received first marketing approval from the US Food and Drug Administration for XYNTHA (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), Trading Markets (press release), Recent patent/copyright infringement cases filed in US District Courts - Feb 21, 2008 Novartis alleges that Wyeth infringes on the patents by making and selling recombinant antihemophilic Factor VIII (known by the trade name ReFacto). Southeast Texas Record, Wyeth's Hemophilia Treatment Given Thumbs Up - Feb 26, 2008 Xyntha (antihemophilic factor [recombinant], plasma/albumin-free) is manufactured using nanofiltration purification technology. FDA news (subscription), Market Report -- In Play (WYE) - Feb 21, 2008 Wyeth's XYNTHA approved by FDA for treatment of hemophilia A Co announces that it has received approval from the FDA for XYNTHA (Antihemophilic Factor MSN Money FDA Okays new hemophilia treatment - Feb 21, 2008 Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free is a genetically engineered version of factor VIII, a protein that is essential for the blood Food Consumer, Dyax Corp. Announces First Market Approval from Licensing and ... - Feb 28, 2008 ...recently received market approval from the US Food and Drug Administration for XYNTHATM (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), WELT ONLINE, Neenah boy's diagnosis gives family a rare insight into bleeding ... - Mar 4, 2008 It is Sebastian's medicine, Helixate FS Antihemophilic Factor (Recombinant). He receives injections every other day in the permanent port installed in his Appleton Post Crescent, Wyeth Receives FDA Approval For Hemophilia A Drug XYNTHA - Update ... - Feb 28, 2008 ...maker Wyeth (WYE), on Thursday said it has received approval from the US Food and Drug Administration for XYNTHA or Antihemophilic Factor (Recombinant), RTT News, DYAX: Wyeth Receives FDA Approval of XYNTHA(TM) for Hemophilia A - Feb 28, 2008 ...(DYAX) announced that Wyeth Pharmaceuticals, a division of Wyeth (WYE), has received market approval from the FDA for XYNTHA(TM) (Antihemophilic Factor Trading Markets (press release), St. Mary Land & Exploration Q4 Adj. Earnings Rise - Quick Facts [SM] - Feb 21, 2008 ...a division of Wyeth (WYE) on Thursday said it received approval from the US Food and Drug Administration for Xyntha or Antihemophilic Factor, RTT News, Hemophilia Drug Approved by FDA - Feb 21, 2008 More precisely, Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free, made by Wyeth Pharmaceuticals, targets patients who suffer from Hemophilia eFluxMedia Baxter Achieves Record Sales and Earnings for Full-Year 2007 - Jan 24, 2008 This growth was driven by double-digit increases across all product categories, including record sales of ADVATE, Antihemophilic Factor (Recombinant), CNNMoney.com CSL Behring Expands Into Middle East Market with Haemate(R) P - 19 Dec 2007 ...such as Haemate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized ; and oral contraceptives to reduce menstrual bleeding BourSonews, Bayer HealthCare Enhances Data Collection of EZ-Log Patient ... - Dec 17, 2007 Now equipped with laser scanners, the enhanced Kogenate® FS, Antihemophilic Factor (Recombinant), EZ-Log Electronic Patient Diary provides more consistent PR Web (press release), Amerinet Announces 2007 Supplier Performance Award Winners - Nov 13, 2007 Healthcare organizations nationwide rely on ASD Healthcare for albumin, immune globulins, hyper-immune globulins, antihemophilic factors, influenza vaccine Business Wire (press release), Baxter Reports Strong Third Quarter Sales and Earnings - Oct 18, 2007 Sales of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a therapy used in the treatment of hemophilia A, exceeded $300 million in PR Newswire (press release), You Can Be Your Own Blood Donor - Sep 21, 2007 ...into multiple components, such as red blood cells, plasma, platelets, and antihemophilic factor, for transfusion to individuals with different needs. Consumer Affairs Prophylactic Use of Recombinant Factor VIII Prevents Joint Disease ... - Aug 9, 2007 About Kogenate(R) FS/KOGENATE(R) Bayer Kogenate(R) FS (Antihemophilic Factor (Recombinant)) is a recombinant factor VIII treatment. CNW Telbec (Communiqués de presse), Prophylactic Use of Recombinant Factor VIII Prevents Joint Disease ... - Aug 9, 2007 Kogenate(R) FS (Antihemophilic Factor (Recombinant)) is a recombinant factor VIII treatment. In Canada, Kogenate(R) FS is indicated for the treatment of PharmaLive.com (press release), Biovitrum Strengthens Its Relationship with Wyeth - Starts to Co ... - Aug 8, 2007 ReFacto Antihemophilic Factor (Recombinant) is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for Business Wire (press release), Baxter Raises 2007 Earnings Guidance Following Strong Second ... - Jul 19, 2007 CNNMoney.comThis performance was a result of robust growth across multiple products, including ADVATE(R) [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Baxter receives FDA approval for new dosage of Advate for hemophilia A - Jul 12, 2007 News-Medical.net,Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method]. Bayer HealthCare Announces New 2000 IU Vial Size for Kogenate(R ... - Jun 29, 2007 PR Newswire (press release),Kogenate(R) FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently Bayer HealthCare Announces New 2000 IU Vial Size for Kogenate(R ... - Jun 29, 2007 PR Newswire (press release),About Kogenate(R) FS Kogenate(R) FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia Bayer HealthCare Announces New 2000 IU Vial Size for Kogenate FS ... - Jun 29, 2007 PharmaLive.com (press release),Kogenate(R) FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently Orphan News :: Treatment & Health - Jun 22, 2007 Checkbiotech.org (press release),The kit also includes an infusion mat, tourniquet, butterfly needles, a biohazard disposal container, flush syringe and ReFacto(R) Antihemophilic Factor Humate-P(R) Approved To Prevent Excessive Bleeding In Patients ... - May 1, 2007 Medical News Today (press release),Humate-P(R) (Antihemophilic Factor/von Willebrand Factor Complex [Human]), CSL Behring's factor replacement therapy for the treatment of hemophilia A and Humate-P(R) Approved to Prevent Excessive Bleeding in Patients ... - Apr 30, 2007 PR Newswire (press release),Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor Talecris Provides Educational Grant to Support World Federation of ... - May 3, 2007 CNW Telbec (Communiqués de presse),..."Our commitment to the hemophilia community goes beyond our offering of Koate(R)-DVI (Antihemophilic Factor (Human)). Not only does this grant improve FDA approves new treatment for von Willebrand disease - May 1, 2007 News-Medical.net,The US Food and Drug Administration (FDA) has approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive Humate-P Approved for Prevention of Excessive Bleeding in von ... - Apr 30, 2007 Facts and Comparisons,The FDA has approved CSL Behring's Humate-P (antihemophilic factor/von Willebrand factor complex [human]) to prevent excessive bleeding during and after FDA Approves Product to Treat Common Bleeding Disorder - Apr 30, 2007 DG NewsROCKVILLE, MD -- April 30, 2007 -- The FDA has approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive FDA OKs drug to treat bleeding disorder - Apr 30, 2007 PhysOrg.com,Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) was approved for prevention of excessive bleeding during and after surgery in certain FDA Approves Product to Treat Common Bleeding Disorder - Apr 30, 2007 Compliance Home,...(April 29, 2007)-- The US Food and Drug Administration (FDA) approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of FDA Approves Drug For Common Bleeding Disorder, Humate-P - Apr 28, 2007 Medical News Today,Humate-P (Antihemophilic Factor/von Willebrand Factor Complex), a drug designed for the treatment of excessive bleeding during and after surgery, ZLB Behring Announces Availability of Humate-P(R) with Smaller Diluent - Apr 12, 2007 Drug Newswire (press release),15 /PRNewswire/ -- ZLB Behring today announced that Humate-P(R) (Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized) is now International Approvals: Solaraze, Nasonex, Advate - Dec 5, 2006 Medscape (subscription)Pharmacokinetics of the drug and antihemophilic factor VIII [recombinant] (Recombinate, also made by Baxter) were assessed in a comparative study reporting ... : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |